Publicaciones en colaboración con investigadores/as de University of Pittsburgh (53)

2024

  1. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

    Nature Genetics, Vol. 56, Núm. 1, pp. 27-36

2023

  1. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  2. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    npj Parkinson's Disease, Vol. 9, Núm. 1

2022

  1. Blueberry juice augments exercise-induced neuroprotection in a Parkinson's disease model through modulation of GDNF levels

    IBRO Neuroscience Reports, Vol. 12, pp. 217-227

  2. Environmental enrichment improves traumatic brain injury-induced behavioral phenotype and associated neurodegenerative process

    Experimental Neurology, Vol. 357

2021

  1. Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

    Journal of Infection, Vol. 83, Núm. 3, pp. 306-313

  3. Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)

    Translational Psychiatry

  4. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  5. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  6. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis

    Human Brain Mapping, Vol. 42, Núm. 2, pp. 439-451

  7. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes

    Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474

  8. Retraction notice: Retraction notice to “Growth factors and beta cell replication” (International Journal of Biochemistry and Cell Biology (2007) 39(11) (2049–2062), (S1357272507001768), (10.1016/j.biocel.2007.05.023))

    International Journal of Biochemistry and Cell Biology

  9. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

  10. Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales

    Movement Disorders Clinical Practice, Vol. 8, Núm. 2, pp. 208-214

2020

  1. Blockade of 5-HT2 receptors with sarpogrelate uncovers 5-HT7 receptors inhibiting the tachycardic sympathetic drive in pithed rats

    Clinical and Experimental Pharmacology and Physiology, Vol. 47, Núm. 3, pp. 403-411

  2. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study

    Neuropsychopharmacology, Vol. 45, Núm. 4, pp. 641-648

  3. Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 5, pp. 567-579

  4. Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association with Clinical Outcome

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 670-679

2019

  1. ADGRL3 (LPHN3) variants predict substance use disorder

    Translational Psychiatry, Vol. 9, Núm. 1